Company Overview
Precision Optics Corporation, Inc. functions as a specialized manufacturer within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States. The company's product portfolio centers on medical instrumentation, offering endoscopes, endocouplers, and other custom imaging solutions to address niche needs in the medical device market. Operating with a workforce of 90 employees, the entity maintains a market capitalization of $32.40M and reported annual revenue of $24.42M over the trailing twelve months. These valuation and revenue figures indicate that the company operates as a micro-cap entity with a relatively small market footprint, suggesting a position limited to specific, specialized segments rather than broad commercial dominance.
Financial Health
The company reported a revenue of $24.42M for the trailing twelve months, yet this revenue base supported a net income of $-6,917,139 and an EBITDA of $-6,477,614, revealing a significant structural disconnect where operating costs and expenses substantially exceed gross earnings. This negative net income relative to revenue indicates a cost structure burdened by high operational overhead or significant losses that are not yet offset by core profitability. The free cash flow stands at $-706,907, which implies that the company is burning cash and lacks the immediate financial flexibility to fund operations or expansion without external capital injection. Margin analysis highlights severe inefficiencies, with a gross margin of 9.7% indicating low pricing power or high cost of goods sold, an operating margin of -23.6% showing that overhead costs are consuming a large portion of revenue, and a profit margin of -28.3% confirming that the company is not retaining earnings after all expenses. On the balance sheet, the company holds $881,486 in cash against total debt of $4.42M, resulting in a debt-to-equity ratio of 47.33, which characterizes a leveraged position where liabilities significantly outweigh liquid assets. The current ratio of 1.05 suggests that the company possesses just enough current assets to cover current liabilities, indicating a precarious short-term liquidity situation with minimal buffer against unexpected cash outflows. Furthermore, the return on equity is -73.6% and the return on assets is -20.8%, metrics that reveal management is currently ineffective at generating value from the capital invested by shareholders or the assets owned by the firm.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is N/A, a mathematical result of the negative earnings that implies the standard price-to-earnings model cannot be used to assess value based on historical or projected profitability. The price-to-book ratio is 3.47, which indicates that the market is valuing the company at a significant premium of over three times its net asset value, a divergence that may reflect high growth expectations or a lack of market consensus regarding the company's true worth. Alternative valuation metrics provide further context, with a price-to-sales ratio of 1.33 suggesting the market prices the company at 1.33 times its revenue, while an EV/EBITDA of -5.54 reflects the negative earnings power inherent in the business model. The stock has traded within a 52-week range bounded by a high of $6.04 and a low of $3.55, meaning the current valuation sits somewhere within this established volatility band, though the exact current price is not provided to calculate the precise percentage distance from the highs or lows. The beta is 0.35, indicating that the stock's price volatility is substantially lower than the broader market, suggesting that the stock moves less aggressively than the S&P 500 during periods of market fluctuation.
Growth & Income
Revenue growth is robust at 62.8% year-over-year, while earnings growth is N/A due to the company's negative net income, implying that the top-line expansion is occurring alongside deepening losses rather than profitability improvements. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests its limited earnings—or rather, its remaining capital—into growth initiatives rather than distributing cash to shareholders. The absence of a dividend yield confirms that the firm is in a reinvestment phase typical of early-stage or turnaround companies, where cash retention is prioritized over income distribution. The overall growth and income profile presents a high-risk scenario characterized by rapid revenue expansion paired with negative earnings and no current income generation for investors.